ACE and hydrops fetalis: In the Biostat-HF and ASIAN-HF registries, women treated with ACE inhibitors, ARBs, and beta-blockers had approximately 30% lower risk of death or hospitalization for heart failure at 50% of the guideline recommended doses (182).